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Implementation of a Clinical Pharmacist in a
Hemodialysis Facility: A Quality Improvement Report
Chantale Daiﬁ, Brian Feldpausch, Pia-Allison Roa, and Jerry Yee
Visual Abstract included

Rationale & Objective: Hemodialysis (HD) patients have complicated disease states, placing
them at higher risk for medication-related
problems,
medication
discrepancies,
and
nonadherence. The objective of this study is to
evaluate the impact of a clinical pharmacist in a
single HD facility by assessing the efﬁcacy of
medication reconciliation in HD patients and
evaluating the potential impact on a single health
care system.

Outcomes: To evaluate the impact of a clinical
pharmacist in an HD facility by assessing the efﬁcacy of medication reconciliation in HD patients
and evaluating the potential impact on this health
system through an estimated cost avoidance.

Complete author and article
information provided before
references.

Analytical Approach: Descriptive statistics were
used to collect medication-related problems and
classiﬁed based on a modiﬁed Hepler-Strand
approach.

Kidney Med. 3(2):241-247.
Published online February
10, 2021.

Study Design: Retrospective study.

Results: There were 1,403 medication-related
problems, with an average of 8.96 medicationrelated problems per patient. Adherence was the
most common medication-related problem (31%).
Antihypertensive medication was the most
common drug class in which the pharmacist
intervened (37%), followed by vitamin D
analogues and calcimimetics (29%). A projected
total of US $447,355 was saved.

© 2021 The Authors.
Published by Elsevier Inc.
on behalf of the National
Kidney Foundation, Inc. This
is an open access article
under the CC BY license
(http://creativecommons.
org/licenses/by/4.0/).

Setting & Participants: Greenﬁeld Health Systems, a wholly owned subsidiary of Henry Ford
Health System, operates 14 HD facilities
throughout Southeast Michigan. The West Pavilion
facility is located in Detroit, MI. Patients with endstage kidney disease included in the study had a
minimum of 4 encounters with the clinical
pharmacist or pharmacy interns between August
2017 and October 2018.
Exposure: A clinical pharmacist performed medication reconciliation and medication reviews with
HD patients to assess medication-related
problems and identify gaps in care. Interventions
made by the pharmacist were prespeciﬁed
through a collaborative practice agreement.

H

doi: 10.1016/
j.xkme.2020.11.015

Limitations: Retrospective analysis of observational data and descriptive statistics with the potential for residual bias and confounding.
Conclusions: Pharmacists in HD facilities have a
positive inﬂuence on HD patients through
medication management that results in cost
savings.

emodialysis (HD) patients have complicated disease
states that frequently require complex medication
regimens. On average, HD patients are prescribed
approximately 11 to 12 medications per day, placing them
at a greater risk for medication-related problems, medication record discrepancies, and nonadherence attributable
in part to comorbid disease states and complex medication
regimens.1,2 A study by Manley et al3 found 1,593
medication-related problems among 395 patients. A
separate analysis by Alshamrani et al4 found 280
medication-related problems in 83 patients. The number
of medication-related problems has an effect on US health
care spending considering that patients with chronic kidney disease and end-stage kidney disease comprise up to
33% of Medicare expenditures.5
Pharmacists are specifically trained in advanced pharmacotherapy to address gaps in care and have been integrated in outpatient settings that demonstrated
improvement in patient outcomes. The positive effects
have stemmed from an ability to assess and prioritize highrisk patients for disease state or medication management,
evaluation of patients for medication adherence, performance of basic assessments such as vital signs and point-
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of-care testing, ordering of laboratory tests, monitoring
of the safety and efficacy of drug therapy, identification of
medication-related barriers, collaboration and consultation
among health care team members, and initiation, adjustment, and discontinuation of therapy.6
Pharmacists have increasingly been implemented as
integral members of health care teams in HD facilities.7
The duties of the clinical pharmacist in an HD unit
include interviewing patients for optimal medication
reconciliation and medication review comparing the patient’s medication list against the physician’s hospital
admission list, transfer, and/or discharge orders, with the
goal of providing correct medications to the patient at all
transition points in their outpatient care. The clinical
pharmacist also provides counseling and patient education,
recommendations and referrals to health care providers,
delivery of a personal medication record to patients,
documentation within the patient’s electronic medical record (EMR), and follow-up visits.
Although the optimal role of a clinical pharmacist in HD
units is still being established, it is important to assess and
evaluate the specific impact of pharmacy services on direct
patient outcomes and cost savings. Several studies have
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PLAIN-LANGUAGE SUMMARY
Patients with end-stage kidney disease are prescribed
multiple medication regimens for management of their
complex disease states. This places them at increased
risk for medication-related problems. Pharmacists are
trained in pharmacotherapy and can directly address
medication-related problems. However, the optimal
role of pharmacists in hemodialysis (HD) facilities has
not been clearly defined. Prior research demonstrated
that integration of a pharmacist in an HD facility provided benefits in multiple areas, including medication
reconciliation and review and resolution of medicationrelated problems. We initiated a program in which a
full-time pharmacist conducted medication reconciliation and review for each patient, with pharmacist interventions through a collaborative practice agreement.
The outcomes of the program included optimization of
medication management, improvement in clinical laboratory outcomes, and cost savings.

documented improved blood pressure (BP) management,
reduced anemia in chronic kidney disease, and improvement in calcium and phosphate levels. The latter have been
associated with reduced mortality, number of hospitalizations, and inpatient length of stay and enhanced cost
savings with clinical pharmacist interventions.8-13
Although these studies show promising outcomes with
pharmacy service intervention, it is important to continually assess patient outcomes and cost savings using
different patient care models.
The primary objective of the study is to evaluate the
impact of a clinical pharmacist in an HD facility by
assessing the efficacy of medication reconciliation and review in HD patients. The secondary objective is to evaluate
the potential impact on the health care system.
METHODS
Study Design
This is a retrospective observational descriptive study that
identified HD patients from Greenfield Health System
(GHS), a dialysis organization that provides dialysis care
for patients with end-stage kidney disease. GHS operates
14 HD facilities in Southeast Michigan, serving approximately 2,000 patients and providing all forms of kidney
replacement therapy. GHS is a wholly owned subsidiary of
Henry Ford Health System. West Pavilion In-Center HD
Unit, a facility in Detroit, has 46 dialysis chairs and accommodates up to 268 patients. All in-center HD adult
patients 18 years or older, both men and women,
receiving in-center HD for a diagnosis of end-stage kidney
disease between August 2017 and October 2018 were
included. Exclusion criteria included patients who were
minors (aged <18 years), resided in a nursing home, or
242

received home HD, peritoneal dialysis, or dialysis for acute
kidney injury. The Henry Ford Health System Institutional
Review Board approved this study (Institutional Review
Board #13159).
Intervention
The dialysis facility consists of an interprofessional team
that includes dieticians, physician assistants, nurse practitioners, nephrologists, and social workers. A clinical
pharmacist was added to the interprofessional team in
2017 as an approach to incorporate a pharmacist-driven
medication reconciliation and review service. Through a
collaborative practice agreement, the pharmacist was able
to order medications and laboratory tests under the scope
of dialysis-related problems. This included managing BP
and chronic kidney disease–mineral and bone disorder.
Incorporation of clinical pharmacy services in this manner
had not existed at this facility before this study.
The clinical pharmacist performed daily medication
reconciliation and medication reviews with each HD patient. Medication reconciliation consisted of the patient or
caregiver bringing in the patient’s home medications so
the pharmacist could accurately identify the medication by
looking at the name and strength. Then the pharmacist
would conduct a 1-on-1 interview with the patient and/or
caregivers that consisted of inquiring how the patient was
taking each medication to identify whether they were
taking it differently from what is directed on the bottle and
if there were any problems the patient was having with
their medications, such as side effects, cost, or tolerability.
After the medication reconciliation was performed, the
pharmacist conducted a medication review to assess
whether there were gaps in patients care, such as any
medication-related problems defined by 9 categories:
adherence, adverse drug reaction, dose too high, dose too
low, needs additional drug therapy, unnecessary drug
therapy, drug-drug interaction, wrong drug, and cost/
accessibility/refills.8 A medication-related problem was
defined as an issue related to one of those categories. The
pharmacist used the collaborative practice agreement to
prescribe or change dialysis and/or BP medications that
were needed under the delegation of a nephrologist. Referrals to physicians were made if care outside of the
collaborative practice agreement boundaries was required.
Some patients required caregiver involvement to reinforce education and medication changes. For patients
requiring caregiver involvement, the caregiver was contacted with patient consent. The pharmacist attempted,
when feasible, to have the caregiver present during
medication reconciliation. If not possible, the caregiver
would be contacted after the pharmacist conducted the
visit with the patient to provide accuracy and updates
regarding the medication regimen.
The findings and changes were documented in the EMR.
This facility operates using an outpatient dialysis EMR
(TIME) separate from the hospital EMR (EPIC). Nonnephrology health care providers use the hospital EMR
Kidney Med Vol 3 | Iss 2 | March/April 2021
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and do not have access to the outpatient dialysis EMR. To
circumvent this software gap in medication reconciliation,
documentation was entered into both EMRs.
Each patient or caregiver was provided with a personalized medication reconciliation and calendar that delineated changes made to the medication regimen. Emphasis
was made on the importance of appropriate medication
administration at correct dosing times. Patients and caregivers were provided with strategies to remember doses.
The pharmacist presented strategies that established routines for when medications should be taken, for example,
on awakening or during meals and before or after dialysis,
as well as how to set alarms or reminders for medication
administration, and encouraged use of the medication
calendar. Pocket pillboxes were given to patients who
missed doses for a variety of reasons. Importantly, when
physical access to medications was difficult or refills were
required, the pharmacist evaluated these situations and
arranged for dialysis chairside medication delivery, using
the outpatient pharmacy associated with the facility.
Follow-up visits were performed a week after the initial
medication reconciliation and on an as-needed basis.
During the visits, the pharmacist reviewed any new laboratory values, vital signs, or changes to medications that
were made from the medication reconciliation. Another
discussion with the patient would occur for a full assessment of how they were tolerating the new regimen. The
patient was given encouraging reinforcement and updates
about the goals of therapy. Additional visits were deemed
necessary if the patient had continued laboratory values
that were not at goal, BP not within threshold, hospitalizations resulting in medication changes, or at patient or
caregiver request.
A patient survey to measure self-reported adherence was
provided to patients who received medication reconciliations and interventions after the third clinical pharmacist
visit. If patients were unable to manage their own medications, adherence survey questions were deferred to the
caregiver. Patients were considered adherent if they reported missing 4 or fewer doses of their medication in the
last month. Patients reported on a scale of 0 to 10, with
0 being the lowest ranking and 10 being the highest
ranking.
Clinical and Laboratory Monitoring
Data were extracted through the internal EHR system.
Extracted data included demographics, dialysis laboratory
values’ 6-month average before pharmacist implementation with no medication reconciliation and 6 months after
pharmacist medication reconciliation (phosphorus, calcium, parathyroid hormone [PTH], and vitamin D) and
BP. Reference laboratory ranges were phosphorus, 2.5 to
5.5 mg/dL; calcium, 8.5 to 10.5 mg/dL; PTH, <300 pg/
dL; and vitamin D, >30 ng/dL.
BP was measured during every dialysis treatment. The
laboratory value criteria used for BP was ≤140/90 mm Hg
defined using Eighth Joint National Committee and
Kidney Med Vol 3 | Iss 2 | March/April 2021

Table 1. Baseline Characteristics
Age, y
BMI, kg/m2
Sex
Male
Female
Race
African American
White
Hispanic
Other
ESKD cause
Hypertension
Diabetes mellitus
Other

All Adults (N = 157)
63.0 [26-92]
27.3 [13.6-53.6]
76 (48%)
81 (52%)
124 (79%)
6 (4%)
9 (6%)
18 (11%)
62 (39%)
10 (6%)
85 (54%)

Note: Values expressed as median [interquartile range] or number (percent).
Abbreviations: BMI, body mass index; ESKD, end-stage kidney disease.

American College of Cardiology/American Heart Association guidelines. The 2014 guidelines were used because
these were the guidelines in place when patients’ BPs were
first assessed. Both systolic and diastolic thresholds had to
be met for the patient to be considered at goal.
Statistical Analysis
Continuous variables are presented as median with interquartile range and categorical variables are presented as
frequency (Table 1). Medication-related problems were

Table 2. Medication-Related Problems Identiﬁed
Medication-Related Problems
Variable
(n = 1,407)
Types of Medication-Related Problems
Adherence
439 (31.3%)
Adverse drug reaction
36 (2.6%)
Dose too high
65 (4.6%)
Dose too low
184 (13.1%)
Needs additional drug therapy 303 (21.5%)
Unnecessary drug therapy
124 (8.8%)
Wrong drug
64 (4.5%)
Additional/other medication9 (0.6%)
related problem
Drug-drug interactions
15 (1.1%)
Cost, accessibility, reﬁlls
168 (11.9%)
Drug Classes Associated With Medication-Related
Problems
Phosphate binders
9%
Vitamin D analogs/
29%
calcimimetics
Supplements
9%
Hypertension
37%
Diabetes
1%
Hypotension
1%
Other
14%
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Table 3. Estimated Cost Avoidance
Drug Class

ECA Level
Level 1: improved quality of care
Level 2: reduced drug product cost
Level 3: avoided physician visit
Level 4: avoided new prescription
Level 5: avoided ED visit
Level 6: avoided hospital admission
Level 7: avoided life–threatening event
Total cost savings

Phosphate
Binder
102
6
7
57
6
—
—

Vitamin D
Analogues/
Calcimimetics
103
3
26
184
10
—
—

Supplements
61
—
2
48
—
—
—

HTN
252
—
28
188
103
—
—

DM
7
—
2
1
—
4
—

Other
155
—
17
9
2
20
—

Total ECA
680
9
82
$19,762
487
121
$149,193
24
$278,400
NA
$447,355

Note: N = 1,407.
Abbreviations: DM, diabetes mellitus; ECA, estimated cost avoidance; ED, emergency department; HTN, hypertension; NA, not applicable.

collected and classified as listed in Table 2. Each
medication-related problem is associated with an estimated
cost avoidance to the health system, defined in Table 3.
Estimated cost avoidance was derived from average national health care use costs using a previously developed
method and are updated annually to reflect inflation.9,10
Levels 3, 5, and 6 have approximate dollar amounts
associated with them and were associated with an estimated cost avoidance of $241, $1,233, and $11,600,
respectively. The model is based primarily on the
medication-related problems and negative therapeutic
outcomes that may occur in the absence of pharmaceutical
care.
RESULTS
A total of 268 patients are dialyzed at GHS West Pavilion
dialysis center. Of those, 157 patients were included in the

study (Fig 1). Overall, 1,407 medication-related problems
were identified, with an average of 8.96 medicationrelated problems per patient. Adherence was found to be
the most common medication-related problem (31%). The
total amount of health care provider interventions made
during the study period was 964, about 6.1 per patient.
The most prevalent interventions were needs additional
drug therapy (21.6%), dose too low (13.1%), and cost/
accessibility/need for refills (11.9%). The most common
drug class for which the pharmacist made interventions
was medications used to treat BP (37%), followed by
vitamin D analogues and calcimimetics (29%).
All medication-related problems were counted and classified to an estimated cost avoidance. It was determined that
82 interventions avoided a physician visit, 121 avoided an
emergency department visit, and 24 avoided a hospital
admission. Each of these had an estimated cost avoidance of
$19,762, $149,193, and $278,400, respectively. A

Figure 1. Patient enrollment.
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Table 4. Patient Survey Results

100

Percent of patients in range

90

Patient Adherence Survey

80
70
60
50
40
30
20
10
0
Blood Pressure

Phosphorus
Pre-MR

Calcium

PTH

Vitamin D

Post-MR

Figure 2. Laboratory characteristics pre– and post–pharmacist
intervention. Abbreviations: MR, medication reconciliation; PTH,
parathyroid hormone.

projected total of US $447,355 was saved after implementation of a clinical pharmacist in the dialysis facility.
Characteristics of laboratory variables are presented in
Fig 2. Phosphorus and calcium levels had an increase of 2%
and 3% in the number of patients within range, respectively,
and similar averages before and after medication reconciliation. Although the percent increase and averages were
similar, there was still a noteworthy number of patients not
within range both pre– and post–laboratory tests. A significant increase in patients in range was seen for PTH and
vitamin D levels, 7% and 13%, respectively, after
intervention.
Before the pharmacist intervention, 43% of patients were
within the BP threshold. After medication reconciliation and
pharmacist interventions, there was a 12% increase in the
number of patients within the BP threshold. Also, BP target
guidelines were met after the pharmacist intervention.
In the post–medication reconciliation follow-up patient
survey, there were 132 respondents (Table 4). The most
significant finding was that 94.7% of patients reported that
the pharmacist helped them understand their medications.
Furthermore, 77% of patients reported adherence to their
medications after medication reconciliation.
DISCUSSION
Our study demonstrates that implementation of a clinical
pharmacist in an HD facility can affect patient care by
resolving medication-related problems, improving clinical laboratory outcomes, and potentially reducing health
care costs through the prevention of hospitalizations,
with reduced lengths of stay and readmissions. The
average number of medication-related problem per patient in our HD cohort was 8.96. The average number of
health care interventions required in our HD patients was
6.1. A recent study demonstrated that HD patients who
were discharged within 30 days from the hospital and
received either partial or full medication therapy
Kidney Med Vol 3 | Iss 2 | March/April 2021

Answer
Results
Q1. Do you ever forget to take your medications?
Yes
88
(66.7%)
No
44
(33.3%)
Q1a. If yes, how many times in the past week/month
would you say you have forgotten to take your
medications?
Adherent (≤4×/mo)
102
(77.3%)
Nonadherent (≥5×/mo)
30
(22.7%)
Q1b. If yes, can you please tell me why?
i. Work
6 (4.5%)
ii. Feeling sick/feeling better
6 (4.5%)
iii. Forgetfulness
44
(33.3%)
iv. Social activities
9 (6.8%)
v. Not getting prescription ﬁlled on time/running out 2 (1.5%)
vi. Cost/ﬁnancial barriers
0 (0%)
vii. Side effects
1 (0.75%)
viii. Other (i.e. busy, tired, running late, not at home, 26
stress)
(19.6%)
Q2. How would you rate your general health?
Scale 0-10
6.9
Q3. How informed do you feel about your medications?
Scale 0-10
8.3
Q4. How comfortable are you with taking your
medications?
Scale 0-10
8.5
Q5. How would you rate your current understanding of
what your medications are used for and how are you
supposed to use them?
Scale 0-10
8.7
Q6. Do you feel the pharmacist has helped you
understand your medications?
Yes
125
(94.7%)
No
7 (5.3%)
Note: Values expressed as mean or number (percent).
Abbreviation: Q, question.

management had an average of 6.3 medication-related
problems per patient.11
Many patients see multiple health care providers to
manage their comorbid conditions or are readmitted into a
hospital multiple times a year. Establishing routine followup with patients following initial medication reconciliation and review is helpful because medications are changed
frequently during patient transitions of care. We have
attributed these barriers to other factors commonly associated with this patient population, including patient education, cultural view of medications, lack of interest in
health care, and financial concerns surrounding
medications.
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A 2-year randomized trial of patients in an HD facility in which medication therapy management services were completed by a pharmacist or standard
medication reviews conducted by nurses revealed that
patients who received medication therapy management
had fewer hospitalizations and decreased lengths of stay
compared with patients who underwent standard
medication reviews by nurses.12 Adherence was the
largest barrier identified and the most challenging to
overcome given its often multifactorial origins. Motivational interviewing techniques and positive reinforcement were used to determine the root cause of
nonadherence.
An investigation by Manley et al11 described the most
common medication-related problem as that related to
dosing issues (31%), that is, dose too high, dose too low,
or the potential for adverse drug reaction(s). This issue was
explored among a general population across 4 states and
has greater generalizability than this analysis of HD patients from a single center.
In our cohort, there was an increase in the number of
patients within range for PTH and vitamin D levels of 7%
and 13%, respectively, and a greater proportion of patients’ BPs were within range after the intervention. We
attribute the positive responses of vitamin D and BP levels
to identification of adherence issues during medication
reconciliation by the pharmacist and pharmacy interns.
Investing in the establishment of strong patient-provider
trust has the potential to augment patient health care interest and a proactive stance toward one’s health care.
Thus, pharmacists not only have proximity to maintenance
HD patients but also the potential to facilitate these positive
outcomes.
We categorized our medication-related problems
into 3 estimated cost avoidance categories and calculated cost savings of US $447,355 during the 6-month
period of observation. The analysis by Ernst and
Grizzle, 13 using a model of drug-related morbidity and
mortality to estimate health care costs associated with
unresolved or unrecognized medication-related problems in the United States ambulatory care population,
estimated that a total of US $76.6 billion was lost due
to medication-related problems. The largest component of this cost was attributed to medication-related
hospitalizations. 9 The investigators updated costs 6
years later, and medication problem–related costs had
more than doubled to US $177.4 billion. 13 The
medication therapy management administrative services company adopted the estimated cost avoidance
model in an effort to delineate the value of pharmacists
to the US health care system. 10 The 7-year study
conducted in a community setting of pharmacists who
provided medication therapy management to patients
determined a mean estimated cost avoidance of US
$93.78 per medication therapy management service
on a single patient.10
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There are limitations of our analysis, which was retrospective with observational data and descriptive statistics.
Residual bias is present because a pharmacist and pharmacy interns conducted the study. However, objective
methods were used as feasible during the collection of
medication-related problems to mitigate confounding.
Also, classification of medication-related problem severity
and quantification of cost through estimated cost avoidance levels bears a degree of subjectivity. This frequently
used method was implemented to yield the most accurate
representation; however, it is difficult to determine exact
costs. Only 227 of 1,407 medication-related problems
were associated with a dollar amount in our total estimated
cost savings. Most of the 1,176 medication-related problems are valuable in that they improved patient care and
cost savings but do not have an associated dollar amount.
Pharmacists can decrease medication-related problems
during patients’ transitions of care among different providers. The integration of pharmacists into an interprofessional team in HD facilities potentially improves patient
outcomes of BP control and increasing vitamin D levels
while reducing health care costs. Overall, this study
demonstrates the benefits of a dedicated HD facility
pharmacist. The close relationship of the pharmacist to
patients and health care providers optimizes medication
management with cost savings through the provision of
appropriate information regarding medications, establishment of trust, and periodic follow-up.
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